Drugs that Target Lipoxygenases and Leukotrienes as Emerging Therapies for Asthma and Cancer

Poff, Candace D.; Balazy, Michael
March 2004
Current Drug Targets - Inflammation & Allergy;Mar2004, Vol. 3 Issue 1, p19
Academic Journal
Considerable amount of work has been done in the area of enzymatic and nonenzymatic oxidation of arachidonic acid. This effort resulted in understanding of the functions of lipid mediators � eicosanoids in various aspects of health and disease. A mechanism by which aspirin exerts therapeutic effects puzzled pharmacologists for a long time until John Vane, in 1971, discovered that aspirin and its congeners block formation of prostaglandins, a class of lipids that originate from oxidation of arachidonic acid by cyclooxygenase. Since that discovery the pharmacology of eicosanoids has substantially progressed, which resulted in new drugs available in clinics. In addition to many new inhibitors of cyclooxygenase, two isoforms of which are known, much effort has been given to find inhibitors of synthesis and function of leukotrienes, a class of lipids that are derived from 5-1ipoxygenase. These lipids are generated in asthma and their uncontrolled biosynthesis aggravates the symptoms of asthma. A new class of drugs called lukasts, inhibitors of 5-LOX products, has been developed and entered clinics as the first new therapy to treat asthma in nearly 20 years. New discoveries in the field of lipoxygenase show great opportunities for drug development for cancer prevention and treatment as it has been established that lipoxygenases and their products are required for cancer growth. Intense research in this field is likely to produce new drugs in the near future.


Related Articles

  • Pranlukast: A Review of its Use in the Management of Asthma. Keam, Susan J.; Lyseng-Williamson, Katherine A.; Goa, Karen L. // Drugs;2003, Vol. 63 Issue 10, p991 

    Pranlukast (Onon[sup ®], Azlaire[sup ®]), is an orally administered, selective, competitive antagonist of the cysteinyl leukotrienes (LT) C[sub 4], LTD[sub 4] and LTE[sub 4]. It is indicated for the prophylactic treatment of chronic bronchial asthma in paediatric and adult patients. The...

  • Inhibition of human É£ -glutamyl transpeptidase: development of more potent, physiologically relevant, uncompetitive inhibitors. WICKHAM, Stephanie; REGAN, Nicholas; WEST, Matthew B.; THAI, Justin; COOK, Paul F.; TERZYAN, Simon S.; Pui Kai LI; HANIGAN, Marie H. // Biochemical Journal;3/15/2013, Vol. 450 Issue 3, p547 

    GGT (É£ -glutamyl transpeptidase) is an essential enzyme for maintaining cysteine homoeostasis, leukotriene synthesis, metabolism of glutathione conjugates and catabolism of extracellular glutathione. Overexpression of GGT has been implicated in many pathologies, and clinical inhibitors of GGT...

  • Bioequivalence study of montelukast tablets in healthy Pakistani volunteers. Abbas, Mateen; Khan, Abdul Muqeet; Amin, Sadia; Riffat, Sualeha; Ashraf, Muhammad; Waheed, Naila // Pakistan Journal of Pharmaceutical Sciences;Mar2013, Vol. 26 Issue 2, p255 

    Montelukast is a leukotrien receptor antagonist used for asthma treatment. Objective of this study was to evaluate the bioequivalence of two montelukast 10mg tablets, Innovator drug (Singulair) as reference and other locally manufactured drug (Montiget) in 12 healthy volunteers. It was...

  • Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Lofdahl, Claes-Goran // BMJ: British Medical Journal (International Edition);07/10/99, Vol. 319 Issue 7202, p87 

    Presents information on a study on the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients. Participants and methods; Results; Conclusions.

  • Leukotriene inhibitors shown to improve asthma patients. Rodgers, Katie // Drug Topics;4/10/95, Vol. 139 Issue 7, p27 

    Reports that leukotriene inhibitors have been shown to improve asthma symptoms and pulmonary functions. Presentation of evidence of zileuton's therapeutic usefulness at the 1995 International Conference of the American Academy of Allergy and Immunology; Improvements noted in patients treated...

  • Recently approved leukotriene cuts the number of days with symptoms and the number of physician...  // Modern Medicine;Apr97, Vol. 65 Issue 4, p16 

    Reports on the effectiveness of a daily regimen of zafirlukast, a leukotriene receptor antagonist, in combination with an as-needed beta agonist in treating patients with mild-to-moderate asthma. Decline in the number of days in which the patients experienced asthmatic symptoms; Decline in the...

  • Drug Info Recently asked Questions.  // South African Pharmaceutical Journal;2013, Vol. 80 Issue 10, p36 

    The article presents questions and answers related to asthma including its treatment, the role of leukotriene as a modifier, and the classification of asthma medicines.

  • Clinical effects of montelukast for chronic asthma in children. Huffman, Grace Brooke // American Family Physician;11/15/1998, Vol. 58 Issue 8, p1895 

    Provides information on the effects of montelukast, a leukotriene receptor antagonist on children with chronic asthma, which was published in the April 15, 198 issue of the `Journal for American Medical Association.' Patients eligible to participate in the study; Onset of action of montelukast.

  • Pranlukast hydrate in the treatment of pediatric bronchial asthma. Shigemi Yoshihara // Pediatric Health, Medicine & Therapeutics;2013, Vol. 4, p55 

    Pranlukast hydrate is a potent, selective, orally active, cysteinyl leukotriene antagonist that binds at the type 1 receptor. It is used as a 10% dry syrup to treat asthma and allergic rhinitis in pediatric patients. In a 4-week, dose-finding study, a dose-dependent improvement in lung function...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics